Research programme: H1/NK1 antagonists - Sanofi-Aventis/Inflazyme

Drug Profile

Research programme: H1/NK1 antagonists - Sanofi-Aventis/Inflazyme

Alternative Names: H1/NK1 antagonists research programme - Aventis/Inflazyme; Histamine H1/neurokinin NK1 antagonists research programme - Aventis/Inflazyme; Research programme: histamine H1/neurokinin NK1 antagonists - Aventis/Inflazyme

Latest Information Update: 18 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Class
  • Mechanism of Action Histamine H1 receptor antagonists; Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Allergic conjunctivitis; Allergic rhinitis

Most Recent Events

  • 12 Jun 2008 Discontinued - Preclinical for Allergic conjunctivitis in North America (Ophthalmic)
  • 12 Jun 2008 Discontinued - Preclinical for Allergic rhinitis in North America (PO)
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top